Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories

Blood (2022) 140 (Supplement 1): 6976–6978.

https://doi.org/10.1182/blood-2022-158671

Published: 2022

Journal Articles

Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS

Andrea Kuendgen, MD, Meritxell Nomdedeu, Heinz Tuechler, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Mikkael A. Sekeres, MD MS, Matteo Giovanni Della Porta, Alan F. List, MD, Mario Cazzola, Amy E. DeZern, MD, Gail J. Roboz, MD, David P. Steensma, MD, Arjan A. Van de Loosdrecht, MD PhD, Hartmut Döhner, MD, Xavier Calvo, MD, Sabine Blum, Arturo Pereira, MD PhD, Peter Valent, Dolors Costa, Aristoteles Giagounidis, Luis Benlloch, Uwe Platzbecker, Carme Pedro, MD, Michael Lübbert, Itziar Oiartzabal, Javier Grau, Maria Díez-Campelo, María Teresa Cedena, Sigrid Machherndl-Spandl, MD, Maria López-Pavía, Claudia D. Baldus, MD, Montserra Martinez-de-Sola, Reinhard Stauder, MD MSc, Brayan Merchan, Christina Ganster, Thomas Schroeder, Barbara Hildebrandt, Jordi Esteve, MD PhD, Benet Nomdedeu, Francesc Cobo, Francesc Sole, PhD, Rainer Haas, MD, Ulrich Germing, MD, Peter L Greenberg, MD, Detlef Haase, MD PhD, Guillermo Sanz

Blood (2018) 132 (Supplement 1): 3103.

https://doi.org/10.1182/blood-2018-99-118215

Published: 2018

Journal Articles

Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Andrea Kuendgen, MD, Heinz Tuechler, Meritxell Nomdedeu, MD, Detlef Haase, MD, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Francesc Sole, PhD, Mikkael A. Sekeres, MD MS, Matteo Giovanni Della Porta, MD, Alan F List, MD, Mario Cazzola, MD, Amy E. DeZern, MD MHS, Gail J. Roboz, David P. Steensma, MD, Arjan A. van de Loosdrecht, MD PhD, Richard F. Schlenk, MD, Xavier Calvo, MD, Sabine Blum, MD, Arturo Pereira, Arturo Pereira, Peter Valent, MD, Dolors Costa, Dolors Costa, Aristoteles Giagounidis, Aristoteles Giagounidis, Luis Benlloch, Uwe Platzbecker, MD, Carmen Pedro, MD, Michael Lübbert, MD, María Teresa Cedena, MD, Julie Schanz, MD, Sigrid Machherndl-Spandl, MD, Maria Lopez-Pavia, MD, María Díez-Campelo, MD, Claudia D. Baldus, MD, Montserrat Martínez de Sola, Reinhard Stauder, MD, Brayan Merchan, MD, Claudia Mende, Maria Teresa Voso, MD, Maria Teresa Voso, MD, Itziar Oiartzabal, Itziar Oiartzabal, Christina Ganster, PhD, Francesc Cobo, Thomas Schroeder, MD, Jordi Esteve, Rainer Haas, MD, Benet Nomdedeu, Peter Greenberg, MD, Ulrich Germing, Guillermo Sanz, MD

Blood (2016) 128 (22): 112.

https://doi.org/10.1182/blood.V128.22.112.112

Published: 2016

Journal Articles

Romiplostim in Thrombocytopenic Patients with Low- or Int-1- Risk MDS Results in Reduced Bleeding without Impacting Leukemic Progression: Final Follow-up Results from a Randomized, Double-Blind, Placebo-Controlled Study

Hagop Kantarjian, Pierre Fenaux, Mikkael A. Sekeres, MD, Jeffrey Szer, Uwe Platzbecker, MD, Andrea Kuendgen, Gianluca Gaidano, Wieslaw Wiktor-Jedrzejczak, MD, Nancy Carpenter, Bhakti Mehta, Janet Franklin, Aristoteles Giagounidis

Blood (2016) 128 (22): 2000.

https://doi.org/10.1182/blood.V128.22.2000.2000

Published: 2016

Journal Articles

Is the IPSS-R Useful for Patients with MDS Receiving Disease-Modifying Treatment?

Sabine Blum, MD, Norbert Gattermann, MD, Filipe Martins, MD, Kathrin Nachtkamp, MD, Andrea Kuendgen, MD, Guido Kobbe, MD, Ulrich Germing

Blood (2016) 128 (22): 5526.

https://doi.org/10.1182/blood.V128.22.5526.5526

Published: 2016

Journal Articles

Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes

Blood (2016) 128 (16): 2096–2097.

https://doi.org/10.1182/blood-2016-07-728766

Published: 2016

Journal Articles

Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia

Blood (2016) 128 (10): 1408–1417.

https://doi.org/10.1182/blood-2016-05-714030

Published: 2016

Includes: Supplemental data

Journal Articles

Time-dependent changes in mortality and transformation risk in MDS

Blood (2016) 128 (7): 902–910.

https://doi.org/10.1182/blood-2016-02-700054

Published: 2016

Includes: Supplemental data

Journal Articles

Incidence and Prognostic Relevance of ASXL2 Mutations in Adult CBF-AML with t(8;21)(q22;q22): A Study of the German-Austrian AML Study Group (AMLSG)

Blood (2015) 126 (23): 3818.

https://doi.org/10.1182/blood.V126.23.3818.3818

Published: 2015

Journal Articles

Clinical Relevance of Minimal Residual Disease Monitoring in NPM1 Mutated AML: A Study of the AML Study Group (AMLSG)

Blood (2015) 126 (23): 227.

https://doi.org/10.1182/blood.V126.23.227.227

Published: 2015

Journal Articles

Romiplostim in Thrombocytopenic Patients (Pts) with Low-Risk or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) Results in Reduced Bleeding without Impacting Leukemic Progression: Updated Follow-up Results from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study

Hagop Kantarjian, MD, Ghulam J. Mufti, MD PhD, Pierre Fenaux, MD PhD, Mikkael A. Sekeres, MD MS, Jeffrey Szer, MB BS FRACP, Uwe Platzbecker, MD, Andrea Kuendgen, MD, Gianluca Gaidano, Wieslaw Wiktor-Jedrzejczak, MD PhD, Janet Franklin, MD MPH, Aristoteles Giagounidis, MD

Blood (2015) 126 (23): 2863.

https://doi.org/10.1182/blood.V126.23.2863.2863

Published: 2015

Journal Articles

Treatment with Azacitidine: A Retrospective Study Evaluating the Real Life Clinical Course and Impact on Infectious Complications

Anna Schuck, MD, Marie Götte, Judith Neukirchen, MD, Andrea Kuendgen, MD, Norbert Gattermann, MD, Guido Kobbe, MD, Ulrich Germing, MD, Rainer Haas, MD

Blood (2015) 126 (23): 1684.

https://doi.org/10.1182/blood.V126.23.1684.1684

Published: 2015

Journal Articles

An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Andrea Kuendgen, MD, Heinz Tuechler, Meritxell Nomdedeu, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Mikkael A. Sekeres, MD MS, Matteo Giovanni Della Porta, MD, Alan F List, MD, Mario Cazzola, Amy E. DeZern, MD MHS, Gail J. Roboz, MD, David P. Steensma, MD, Arjan A van de Loosdrecht, MD PhD, Arjan A van de Loosdrecht, MD PhD, Richard F. Schlenk, MD, Xavier Calvo, Sabine Blum, Arturo Pereira, Peter Valent, MD, Dolors Costa, Aristoteles Giagounidis, MD PhD, Luis Benlloch, Uwe Platzbecker, MD, Carmen Pedro, MD, Michael Lübbert, MD, Maria Teresa Cedena, Sigrid Machherndl-Spandl, MD, Maria Lopez-Pavia, MD, Detlef Haase, MD, Ana Africa Martin, Claudia D Baldus, MD, Montserrat Martínez de Sola, Reinhard Stauder, MD MSc, Brayan Merchan, MD, Claudia Mende, María Teresa Ardanaz, MD, Christina Ganster, Francesc Cobo, Thomas Schroeder, MD, Jordi Esteve, Rainer Haas, MD, Nomdedeu Benet, Peter L. Greenberg, MD, Ulrich Germing, MD, Guillermo Sanz, MD PhD

Blood (2015) 126 (23): 609.

https://doi.org/10.1182/blood.V126.23.609.609

Published: 2015

Journal Articles

Monitoring of Minimal Residual Disease (MRD) of DNMT3A Mutations (DNMT3A mut ) in Acute Myeloid Leukemia (AML): A Study of the AML Study Group (AMLSG)

Blood (2015) 126 (23): 226.

https://doi.org/10.1182/blood.V126.23.226.226

Published: 2015

Journal Articles

Survey of Treatment of 1021 Patients with Myelodysplastic Syndromes in a Tertiary Referal Center 2007-2013

Jennifer Schemenau, Kathrin Nachtkamp, MD, Blanca Xicoy, MD PhD, Andrea Kuendgen, MD, Corinna Strupp, MD, Thomas Schroeder, MD, Esther Schuler, Guido Kobbe, MD, Norbert Gattermann, MD, Rainer Haas, MD, Ulrich Germing

Blood (2014) 124 (21): 4647.

https://doi.org/10.1182/blood.V124.21.4647.4647

Published: 2014

Journal Articles

In MDS Del(5q), Factors Other Than Age and Sex Distribution Contribute to the Prognostic Advantage, Which Diminishes over Time

Michael Lauseker, PhD, Jennifer Schemenau, Corinna Strupp, MD, Andrea Kuendgen, MD, Norbert Gattermann, MD, Joerg Hasford, MD, Ulrich Germing, MD

Blood (2014) 124 (21): 3271.

https://doi.org/10.1182/blood.V124.21.3271.3271

Published: 2014

Journal Articles

Treatment with Romiplostim, a Thrombopoietin-Receptor Agonist, in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndrome (MDS): Updated Follow-up Results for Acute Myeloid Leukemia (AML) and Survival from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study

Hagop M. Kantarjian, Ghulam Mufti, Pierre Fenaux, Mikkael Sekeres, Jeffrey Szer, Uwe Platzbecker, Andrea Kuendgen, MD, Gianluca Gaidano, Wieslaw Wiktor-Jedrzejczak, Amelia Orejudos, Angela Lopez, Aristoteles Giagounidis

Blood (2014) 124 (21): 3276.

https://doi.org/10.1182/blood.V124.21.3276.3276

Published: 2014

Journal Articles

Somatic Mutations of ASXL1 , RUNX1 and SETBP1 Improve Prognostic Stratification of Patients with Chronic Myelomonocytic Leukemia

Chiara Elena, MD, Anna Gallì, PhD, Esperanza Such, PhD, Ulrich Germing, Ettore Rizzo, PhD, Jose Cervera, MD, Elisabetta Molteni, PhD, Esther Schuler, Ilaria Ambaglio, MD, Maria Lopez-Pavia, Silvia Zibellini, PhD, Andrea Kuendgen, MD, Erica Travaglino, Reyes Sancho-Tello, Matteo G Della Porta, MD, Ana Isabel Vicente, Guillermo F. Sanz, MD PhD, Luca Malcovati, MD, Mario Cazzola, MD

Blood (2014) 124 (21): 1915.

https://doi.org/10.1182/blood.V124.21.1915.1915

Published: 2014

Journal Articles

A Phase II Study of Valproic Acid and Lenalidomide Combination Therapy in Patients with Myelodysplastic Syndrome (MDS) and a Favorable Risk Proﬁle: Final Results of the Valena Trial

Andrea Kuendgen, MD, Michael Lübbert, Richard F. Schlenk, MD, Uwe Platzbecker, MD, Detlef Haase, Torsten Haferlach, Susanne Schnittger, PhD, Aristoteles Giagounidis, Carolin Brings, Ulrich Germing, MD, Rainer Haas, MD, Norbert Gattermann, MD

Blood (2014) 124 (21): 1918.

https://doi.org/10.1182/blood.V124.21.1918.1918

Published: 2014

Journal Articles

Possible Biomarkers To Predict Response In Patients With Myelodysplastic Syndromes (MDS) Or Acute Myeloid Leukemia (AML) Treated With 5-Azacitidine

Andrea Kuendgen, MD, Catharina Müller-Thomas, MD, Petra Urbaniak, Michael Lauseker, Torsten Haferlach, MD, Tamara Alpermann, Andreia Albuquerque, PhD, Alexander Kohlmann, PhD, Susanne Schnittger, PhD, Barbara Hildebrandt, PhD, Brigitte Royer-Pokora, PhD, Norbert Gattermann, MD, Rainer Haas, MD, Ulrich Germing, MD, Katharina Götze, MD

Blood (2013) 122 (21): 2757.

https://doi.org/10.1182/blood.V122.21.2757.2757

Published: 2013

NARROW

Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories

Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS

Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Romiplostim in Thrombocytopenic Patients with Low- or Int-1- Risk MDS Results in Reduced Bleeding without Impacting Leukemic Progression: Final Follow-up Results from a Randomized, Double-Blind, Placebo-Controlled Study

Is the IPSS-R Useful for Patients with MDS Receiving Disease-Modifying Treatment?

Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes

Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia

Time-dependent changes in mortality and transformation risk in MDS

Incidence and Prognostic Relevance of ASXL2 Mutations in Adult CBF-AML with t(8;21)(q22;q22): A Study of the German-Austrian AML Study Group (AMLSG)

Clinical Relevance of Minimal Residual Disease Monitoring in NPM1 Mutated AML: A Study of the AML Study Group (AMLSG)

Romiplostim in Thrombocytopenic Patients (Pts) with Low-Risk or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) Results in Reduced Bleeding without Impacting Leukemic Progression: Updated Follow-up Results from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study

Treatment with Azacitidine: A Retrospective Study Evaluating the Real Life Clinical Course and Impact on Infectious Complications

An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Monitoring of Minimal Residual Disease (MRD) of DNMT3A Mutations (DNMT3A mut ) in Acute Myeloid Leukemia (AML): A Study of the AML Study Group (AMLSG)

Survey of Treatment of 1021 Patients with Myelodysplastic Syndromes in a Tertiary Referal Center 2007-2013

In MDS Del(5q), Factors Other Than Age and Sex Distribution Contribute to the Prognostic Advantage, Which Diminishes over Time

Somatic Mutations of ASXL1 , RUNX1 and SETBP1 Improve Prognostic Stratification of Patients with Chronic Myelomonocytic Leukemia

A Phase II Study of Valproic Acid and Lenalidomide Combination Therapy in Patients with Myelodysplastic Syndrome (MDS) and a Favorable Risk Proﬁle: Final Results of the Valena Trial

Possible Biomarkers To Predict Response In Patients With Myelodysplastic Syndromes (MDS) Or Acute Myeloid Leukemia (AML) Treated With 5-Azacitidine

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only